DOJ closes FCPA probe into Misonix
By 
Jaclyn Jaeger2019-08-21T14:55:00
The DOJ has now closed its investigation into medical device company Misonix—about a month after the SEC closed its probe—without bringing enforcement actions. The FCPA investigation still resulted in some extensive anti-corruption compliance reforms.
Related articles
-
ArticleSEC closes FCPA probe into Misonix
The SEC has closed its FCPA investigation into medical device company Misonix and will not be recommending an enforcement action, the company announced.
-
Blog
Misonix discloses FCPA investigation
Medical-device maker Misonix said it voluntarily contacted the Securities and Exchange Commission and the U.S. Department of Justice this week to inform them about potential violations of the Foreign Corrupt Practices Act. Jaclyn Jaeger reports.
-
Basic Page‘Extraordinary cooperation’ pays off for PFS Investments
As regulators shift toward rewarding transparency, self-regulation and self-reporting, the way PFS Investments handled a longstanding problem serves as an example of how proactive remediation can turn a costly compliance error into a manageable regulatory outcome.
More from Anti-Bribery
-
PremiumBribery risk elevated, experts say, as DOJ narrows FCPA enforcement
When the U.S. Department of Justice announced a six-month enforcement pause of the Foreign Corrupt Practices Act (FCPA) in February, many speculated that the risks posed by bribery had been lowered. So when the DOJ said last week that it would resume launching FCPA investigations, it may just seem like ...
-
PremiumAfter a six-month enforcement pause, DOJ will again pursue FPCA investigations
The Department of Justice has ended its six-month FCPA enforcement pause, closed half its legacy bribery cases, and will now pursue foreign bribery probes aligned with President Donald Trump’s priorities.
-
News BriefIn continuing re-evaluation of FCPA cases, DOJ ends Albemarle FCPA reporting
The Department of Justice has ended another FCPA-related compliance action more than a year early. This scaling back of regulatory enforcement by the federal government has been a growing trend since the start of the Trump administration.